The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature

被引：21

作者：

Tsikouras, Panagiotis ^{[1
]}

Tsagias, Nikolaos ^{[1
]}

Pinidis, Petros ^{[1
]}

Csorba, Roland ^{[2
]}

Vrachnis, Nikolaos ^{[3
]}

Dafopoulos, Alexandros ^{[1
]}

Bouchlariotou, Sophia ^{[1
]}

Liberis, Anastasios ^{[1
]}

Teichmann, Alexander Tobias ^{[2
]}

von Tempelhoff, Georg Friedrich ^{[2
]}

机构：

[1] Democritus Univ Thrace, Dept Obstet & Gynecol, Alexandroupolis, Greece

[2] Univ Wurzburg, Teaching Hosp, Clinicum Aschaffenburg, Dept Obstet & Gynecol, Aschaffenburg, Germany

[3] Univ Athens, Sch Med, Aretaiteio Hosp, Dept Obstet & Gynecol 2, GR-11527 Athens, Greece

来源：

ARCHIVES OF GYNECOLOGY AND OBSTETRICS | 2013年 / 288卷 / 03期

关键词：

Catumaxomab; Malignant ascites; Ovarian cancer; STAGE-III OVARIAN; EPCAM X ANTI-CD3; ANTIBODY; MANAGEMENT; RECURRENT; CELLS; IMMUNOTHERAPY; CHEMOTHERAPY; INHIBITOR; CARCINOMA;

D O I：

10.1007/s00404-013-2868-y

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

The approval of the first specific drug catumaxomab for the treatment of malignant ascites is the subject of this review. This trifunctional antibody is known to kill EpCAM-positive tumor cells and therefore attacks the primary cause of malignant ascites formation in the peritoneal cavity. Until today catumaxomab is the only EpCam-targeted antibody approved by the European Medicines Agency. Ovarian cancer is caused by epithelial tumors cells which overexpress epithelial cell adhesion molecule (EpCAM). The existing literature concerning the use of catumaxomab for the treatment of malignant ascites associated with ovarian cancer until today is reported in this article. It is very encouraging that different prospective studies from diverse scientific teams recently presented positive results concerning the efficacy and the safety of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer. A case of a patient with ovarian cancer FIGO IIIc is also referred in this article. A complete remission and stable disease was found after 4 i.p. infusions of catumaxomab.

引用

页码：581 / 585

页数：5

共 39 条

[1] Pattern and prognostic factors in patients with malignant ascites: a retrospective study [J].

Ayantunde, A. A. ;

Parsons, S. L. .

ANNALS OF ONCOLOGY, 2007, 18 (05) :945-949

[2] The biology of the 17-1A antigen (Ep-CAM) [J].

Balzar, M ;

Winter, MJ ;

de Boer, CJ ;

Litvinov, SV .

JOURNAL OF MOLECULAR MEDICINE-JMM, 1999, 77 (10) :699-712

[3] A novel perspective for an orphan problem: Old and new drugs for the medical management of malignant ascites [J].

Barni, S. ;

Cabiddu, M. ;

Ghilardi, M. ;

Petrelli, F. .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 79 (02) :144-153

[4]

Beattie GJ, 1998, CLIN CANCER RES, V4, P1899

[5]

Belau A, 2007, J CLIN ONCOL, V25

[6] Trials With Impact on Clinical Management First Line [J].

Bookman, Michael A. .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 :S55-S62

[7] Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody:: A phase I/II study [J].

Burges, Alexander ;

Wimberger, Pauline ;

Kuemper, Carolin ;

Gorbounova, Vera ;

Sommer, Harald ;

Schmalfeldt, Barbara ;

Pfisterer, Jacobus ;

Lichinitser, Michail ;

Makhson, Anatoliy ;

Moiseyenko, Vladimir ;

Lahr, Angelika ;

Schulze, Elisabeth ;

Jaeger, Michael ;

Stroehlein, Michael A. ;

Heiss, Markus Maria ;

Gottwald, Thomas ;

Lindhofer, Horst ;

Kimmig, Rainer .

CLINICAL CANCER RESEARCH, 2007, 13 (13) :3899-3905

[8] Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? [J].

Cannistra, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1158-1160

[9] Evaluating New Regimens in Recurrent Ovarian Cancer: How Much Evidence Is Good Enough? [J].

Cannistra, Stephen A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3101-3103

[10]

Chekerov R, 2010, AM SOC CLIN ONCOLO S, V28, P5039

← 1 2 3 4 →